AVRO AVROBIO Inc.

19.6
-1.09  -5%
Previous Close 20.69
Open 20.76
Price To Book 3
Market Cap 620,690,860
Shares 31,667,901
Volume 116,104
Short Ratio
Av. Daily Volume 203,436
Stock charts supplied by TradingView

NewsSee all news

  1. AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program

    FDA clears IND application for AVR-RD-02 First patient consented in GAU-201, a global Phase 1/2 trial of AVR-RD-02 in Gaucher disease type 1 All global clinical sites will be supported by proprietary plato™

  2. AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO (NASDAQ:AVRO) (the "Company"), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock

  3. AVROBIO Announces First Patient Dosed Using plato™ Platform

    Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease plato is AVROBIO's platform for worldwide gene therapy commercialization AVROBIO (NASDAQ:AVRO) (the

  4. AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO (NASDAQ:AVRO) (the "Company"), a leading clinical stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock

  5. AVROBIO, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    Dosing of first Fabry patient incorporating plato™ anticipated for fourth quarter 2019 All Fabry patients who discontinued enzyme replacement therapy (ERT) following treatment with AVR-RD-01 investigational gene

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 initial data due 2020.
AVR-RD-04
Cystinosis
Phase 1/2 trial initial data due 2020.
AVR-RD-02
Gaucher disease
Phase 2 preliminary data released July 15, 2019. Further data due 2020.
AVR-RD-01 (FAB-201)
Fabry disease

Latest News

  1. AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program

    FDA clears IND application for AVR-RD-02 First patient consented in GAU-201, a global Phase 1/2 trial of AVR-RD-02 in Gaucher disease type 1 All global clinical sites will be supported by proprietary plato™

  2. AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO (NASDAQ:AVRO) (the "Company"), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock

  3. AVROBIO Announces First Patient Dosed Using plato™ Platform

    Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease plato is AVROBIO's platform for worldwide gene therapy commercialization AVROBIO (NASDAQ:AVRO) (the

  4. AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO (NASDAQ:AVRO) (the "Company"), a leading clinical stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock

  5. AVROBIO, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    Dosing of first Fabry patient incorporating plato™ anticipated for fourth quarter 2019 All Fabry patients who discontinued enzyme replacement therapy (ERT) following treatment with AVR-RD-01 investigational gene

  6. AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR‑RD‑02 for the Treatment of Gaucher Disease

    AVROBIO, Inc. (NASDAQ:AVRO) (the "Company"), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company's investigational gene therapy, AVR-RD-02, for the

  7. AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis

    Investigational Therapy Designed to Engineer Patients' Own Stem Cells to Produce Essential Protein AVROBIO, Inc. (NASDAQ:AVRO) (the "Company") today announced that the first patient has been dosed in the Company's

  8. AVROBIO, Inc. to Present at Chardan's 3rd Annual Genetic Medicines Conference

    AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan's 3rd Annual Genetic Medicines Conference on Monday,

  9. AVROBIO, Inc. to Present at Upcoming Investor Conferences

    AVROBIO, Inc. (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that members of its senior management team are scheduled to participate in five upcoming investor conferences. Citi's 14th